UNSPSC 51342311: Aciclovir sodium

This classification denotes a purine antagonist and antiviral agent with the molecular formula C8H10N5O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 927L42J563, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-, monosodium salt but more generally known as aciclovir sodium, which bears US NIH Compound Identifier 50600. The base compound, Aciclovir, also known as acyclovir, also comes in base and natrium forms.

European Medicines Agency schedules Aciclovir sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00284MIG. Most nations, for tariff and trade purposes, schedule aciclovir sodium under HS 29335995. SMILES: C1NC2C(=O)[N-]C(NC2N1COCCO)N.[NA+].

UNSPSC 51342311 Aciclovir sodium is a Commodity code that nominally covers pharmaceutical products, but the recent state and local contract opportunities posted under this code show little direct relevance to aciclovir supply itself. Instead, the opportunities reflect broader pharmaceutical procurement activity by state health departments and counties, including antibiotic tablets, naloxone, and drug deactivation systems. State and local issuing bodies use this code or related pharmaceutical codes to organize emergency preparedness, public health, and community health initiatives, often leveraging cooperative purchasing vehicles such as the MMCAP Infuse consortium to aggregate volume and negotiate fixed-term supply agreements with pharmaceutical distributors and vendors.

Activity under the code appears concentrated in the Southeast and Midwest. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over the contract term with 12-month initial and two-year renewal options; Seminole County, Florida issued an IFB on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a two-year term with one-year renewal option. Neither opportunity directly solicits aciclovir; the code's nominal scope and the actual work being bought do not align closely in the available record.